Subscribe to RSS
DOI: 10.1055/s-0043-1766382
Clinical benefit of 18F-FET-PET/CT in children and adolescents with central nervous system tumors
Ziel/Aim Positron emission tomography/computed tomography (PET/CT) with O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) is a well-established tool for the non-invasive assessment of adult central nervous system (CNS) tumors. However, data on its diagnostic utility and impact on clinical management in children and adolescents is limited.
Methodik/Methods 21 children and young adults (13 males; mean age, 9.3±5.2 years; range, 1-19 at initial diagnosis) with either newly diagnosed (n=5) or pre-treated (n=16) CNS tumors were retrospectively analyzed. All patients had previously undergone neuro-oncological work-up including cranial magnetic resonance imaging. In all cases, [18F]FET PET/CT was indicated in a multidisciplinary team conference. The impact of PET imaging on clinical decision making was assessed. Histopathology (n=12) and/or clinical and imaging follow-up (n=9) served as the standard of reference.
Ergebnisse/Results Addition of [18F]FET-PET/CT to the available information had an impact on further patient management in 14 out of 21 subjects, with avoidance of invasive surgery or biopsy in four patients, biopsy guidance in four patients, change of further treatment in another five patients, and confirmation of diagnosis in one patient.
Schlussfolgerungen/Conclusions [18F]FET-PET/CT can provide important additional information for treatment guidance in pediatric and adolescent patients with CNS tumors.
Publication History
Article published online:
30 March 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany